Business Context and Reporting Period
This Form 8-K Current Report was filed by Wave Life Sciences Ltd. on January 10, 2020, covering events occurring on January 9, 2020. The registrant is incorporated in Singapore and its ordinary shares trade on The Nasdaq Global Market under the symbol "WVE".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report is limited to corporate governance and personnel changes.
Material Changes
The filing discloses the following material changes to executive leadership:
- Resignation: Keith C. Regnante resigned as Chief Financial Officer effective January 9, 2020, to pursue other opportunities. His resignation was not due to any disagreement with the Company or its Board regarding operations, policies, or practices.
- Appointment: David Gaiero was appointed as Interim Chief Financial Officer, principal accounting officer, and principal financial officer effective January 9, 2020.
- Transition: Mr. Regnante will assist with the transition of responsibilities through January 31, 2020.
Management Commentary and Risks
Management confirmed that the departure of the CFO was amicable and unrelated to any disputes. Mr. Gaiero, who has served as Vice President, Corporate Controller since July 2017, brings prior experience from OvaScience, Inc., iRobot Corporation, and PricewaterhouseCoopers, LLP. No unusual items, contingencies, or forward-looking guidance were disclosed in this specific filing.
Investor Verification Checklist
- Verify the effective date of the CFO transition (January 9, 2020).
- Confirm the interim status of the new CFO appointment.
- Review the Company's subsequent filings for the appointment of a permanent CFO.
- Check for any related compensation arrangements or severance agreements not detailed in this summary.